Table 1 In vitro susceptibility pattern of MBL producing and non-MBL-producing isolates of E. coli and K. pneumoniae by disc diffusion test
Antibiotics tested | % sensitive | |||
|---|---|---|---|---|
E. coli (n = 216) | K. pneumoniae (n = 185) | |||
Non-MBL producer (n = 175) | MBL producer (n = 41) | Non-MBL producer (n = 146) | MBL producers (n = 39) | |
Ampicillin (10 μg) | 2.85 | 0.00 | 0.00 | 0.00 |
Cephalothin (30 μg) | 16.57 | 0.00 | 13.69 | 0.00 |
Cefpodoxime (10 μg) | 35.42 | 0.00 | 33.56 | 0.00 |
Ceftazidime (30 μg) | 40.57 | 0.00 | 37.67 | 0.00 |
Cefotaxime (30 μg) | 38.85 | 0.00 | 39.72 | 0.00 |
Ceftriaxone (30 μg) | 43.42 | 0.00 | 42.46 | 0.00 |
Cefepime (30 μg) | 46.85 | 0.00 | 44.52 | 0.00 |
Aztreonam (30 μg) | 40.0 | 0.00 | 41.09 | 0.00 |
Cefoxitin (30 μg) | 64.57 | 0.00 | 69.18 | 0.00 |
Piperacillin/tazobactam (100/10 μg) | 82.85 | 0.00 | 77.39 | 0.00 |
Imipenem (10 μg) | 100.00 | 0.00 | 100.00 | 0.00 |
Meropenem (10 μg) | 100.00 | 0.00 | 100.00 | 0.00 |
Ertapenem (10 μg) | 100.00 | 0.00 | 100.00 | 0.00 |
Ciprofloxacin (5 μg) | 64.00 | 7.31 | 67.12 | 10.25 |
Levofloxacin (5 μg) | 85.14 | 24.39 | 87.67 | 28.20 |
Co-Trimoxazole | 61.14 | 0.00 | 65.75 | 7.69 |
Gentamicin (10 μg) | 72.57 | 17.07 | 70.54 | 15.38 |
Amikacin (30 μg) | 80.57 | 21.95 | 78.08 | 20.51 |
Tigecycline (15 μg) | 100.00 | 100.00 | 100.00 | 100.00 |
Colistin (10 μg) | 100.00 | 100.00 | 100.00 | 100.00 |